Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 3/20 | 0.46 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | NPY2R | P49146 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14421361 | 0.98 | LMNA (0.46) | CETPP2RX7LMNAAKR1C1TSHR | |
| SCHEMBL8151048 | 0.90 | LMNA (0.48) | LMNATSHRCYP3A4HPGDKMT2A | |
| SCHEMBL20228048 | 0.81 | SIGMAR1 (0.44) | LMNATSHRALDH1A1 | |
| SCHEMBL1431419 | 0.80 | LMNA (0.44) | LMNAAKR1C1TSHRHPGDHDAC4 | |
| SCHEMBL1446381 | 0.80 | LMNA (0.44) | LMNAAKR1C1TSHRHPGDHDAC4 | |
| SCHEMBL14040096 | 0.79 | CES2 (0.52) | LMNAHPGDKMT2AALDH1A1CES2 | |
| SCHEMBL29155399 | 0.79 | AKR1C1 (0.45) | LMNAAKR1C1TSHRCYP3A4HPGD | |
| SCHEMBL8529984 | 0.79 | AKR1C1 (0.45) | LMNAAKR1C1TSHRCYP3A4HPGD | |
| Methyl Alcohol SCHEMBL28651962 | 0.78 | KDM4E (0.44) | LMNAAKR1C1TSHRCYP3A4HPGD | |
| SCHEMBL28095639 | 0.78 | KDM4E (0.44) | LMNAAKR1C1TSHRCYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 221 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10738204-B2 | Printing process for preparing controlled scattering effects | XEROX CORPORATION (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190322881-A1 | Printing Process For Preparing Controlled Scattering Effects | XEROX CORPORATION | 2019-10-24 | — | — | US | disclosed |
| US-9941543-B2 | Non-aqueous liquid electrolyte for secondary battery and secondary battery | FUJIFILM CORPORATION (JP) | 2018-04-10 | — | — | US | disclosed |
| US-9782771-B2 | Method for making hydrophobic barriers requiring UV-light treatment | XEROX CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-9782771-B2 | Method for making hydrophobic barriers requiring UV-light treatment | XEROX CORPORATION (US) | 2017-10-10 | — | — | US | disclosed |
| US-20170210922-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2017-07-27 | — | — | US | disclosed |
| US-20170210922-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2017-07-27 | — | — | US | disclosed |
| US-9676952-B2 | 3D printing system comprising solid build ink comprising colorant | XEROX CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676952-B2 | 3D printing system comprising solid build ink comprising colorant | XEROX CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160244628-A1 | 3D PRINTING SYSTEM COMPRISING SOLID BUILD INK COMPRISING COLORANT | XEROX CORPORATION | 2016-08-25 | — | — | US | disclosed |
| US-20080000384-A1 | RADIATION CURABLE INK CONTAINING GELLANT AND RADIATION CURABLE WAX | XEROX CORPORATION (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080000384-A1 | RADIATION CURABLE INK CONTAINING GELLANT AND RADIATION CURABLE WAX | XEROX CORPORATION (US) | 2008-01-03 | — | — | US | disclosed |
| US-20070283846-A1 | Organic Phase Change Carriers Containing Nanoparticles, Phase Change Inks Including Same and Methods for Making Same | XEROX CORPORATION (US) | 2007-12-13 | — | — | US | disclosed |
| US-20070283846-A1 | Organic Phase Change Carriers Containing Nanoparticles, Phase Change Inks Including Same and Methods for Making Same | XEROX CORPORATION (US) | 2007-12-13 | — | — | US | disclosed |
| US-7279587-B2 | Photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION (US) | 2007-10-09 | — | — | US | disclosed |
| US-7279587-B2 | Photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION (US) | 2007-10-09 | — | — | US | disclosed |
| US-20070123723-A1 | Photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070123723-A1 | Photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070120910-A1 | Phase change inks containing photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
| US-20070120910-A1 | Phase change inks containing photoinitiator with phase change properties and gellant affinity | XEROX CORPORATION | 2007-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123723-A1 | Photoinitiator with phase change properties and gellant affinity | NR2E3, NR4A1, NR4A3 | CETP 1662/4885P2RX7 3534/4885LMNA 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.